FDA Moves to Ease Restrictions on Unapproved Therapeutic Peptides
Advisory panel review announced for July 2026 — compounding access to 12 peptides under consideration
The U.S. Food and Drug Administration announced on April 15, 2026 that it will convene an expert advisory panel to consider easing compounding restrictions on more than a dozen unapproved peptide injections — a class of therapies that have grown significantly in popularity among wellness communities, anti-aging advocates, and athletes, despite limited clinical trial data.
The announcement marks a significant policy reversal from the FDA's 2023 crackdown, when the agency removed 19 peptides from the list of substances compounding pharmacies are permitted to produce. It follows repeated public pledges by Health and Human Services Secretary Robert F. Kennedy Jr. to loosen regulatory restrictions on peptides, and comes after Kennedy previewed the move in an interview with podcaster Joe Rogan in February 2026.
BACKGROUND
In late 2023, the FDA placed 19 widely used peptides on its Category 2 restricted list, effectively prohibiting compounding pharmacies from preparing them for patients. At the time, the FDA's Pharmacy Compounding Advisory Committee voted overwhelmingly that the peptides did not meet criteria for safe compounding, with the agency subsequently citing "significant safety risks" arising from limited human testing.
The restrictions had immediate practical consequences: compounding pharmacies — which mix customised medications not otherwise available from commercial manufacturers — could no longer fill prescriptions for these peptides. Critics, including compounding industry groups and integrative medicine advocates, argued the move pushed patients toward unregulated gray-market sources, including overseas suppliers offering peptides labelled "for research use only" with no pharmaceutical quality controls.
WHAT WAS ANNOUNCED — APRIL 15, 2026
The FDA issued a federal notice announcing two advisory committee meetings of the Pharmacy Compounding Advisory Committee (PCAC):
• Meeting 1: July 23–24, 2026 — review of seven peptides
• Meeting 2: Before February 28, 2027 — review of a further five peptides
The panel will consider whether each peptide should be added to the list of substances that can be safely produced by compounding pharmacies. Separately, the FDA indicated it will soon remove these substances from the restrictive Category 2 list while the review process proceeds — a meaningful interim step that reduces enforcement exposure for compounders.
GROUP 1 — JULY 2026 PANEL (7 PEPTIDES)
Peptide
Proposed Therapeutic Use
BPC-157
Ulcerative colitis; tissue repair and inflammation
TB-500 (Thymosin Beta-4)
Wound healing; muscle repair and recovery
KPV
Wound healing; anti-inflammatory
MOTS-C
Obesity management; osteoporosis
Emideltide
Sleep disorders
Epitalon
Sleep disorders; longevity research
Semax
Cognitive function support
GROUP 2 — SECOND MEETING, BEFORE FEBRUARY 2027 (5 PEPTIDES)
Peptide
Proposed Therapeutic Use
CJC-1295
Growth hormone release; sleep and metabolism
Ipamorelin
Growth hormone release; lean muscle support
Thymosin Alpha-1
Immune modulation; infectious disease support
AOD-9604
Fat metabolism
Selank
Anxiety; stress resilience; immune support
Note: The Group 2 list reflects substances referred to the PCAC in September 2024 and is pending formal confirmation in the FDA's published federal notice.
REGULATORY CONTEXT — WHAT 'CATEGORY 1' MEANS
A Category 1 designation means the FDA has reviewed a nominated bulk drug substance and determined it does not appear to present significant safety risks, allowing licensed compounding pharmacies to prepare it under a physician's prescription pursuant to Sections 503A/503B of the Federal Food, Drug, and Cosmetic Act.
Critically, Category 1 is not the same as FDA approval. These peptides have not undergone the full New Drug Application (NDA) process — including Phase I, II and III clinical trials — required for an approved drug. They remain unapproved substances dispensed under physician discretion, with no established label claims for safety or efficacy.
WHAT HAPPENS NEXT
• The PCAC advisory meeting on July 23–24 will produce non-binding recommendations to the FDA.
• The FDA must then draft and publish formal rule changes — a process that typically takes several months beyond the advisory stage.
• Kennedy could appoint new members to the PCAC before July, given current vacancies on the panel.
• A second meeting covering five additional peptides is to be convened before the end of February 2027.
• Practitioners and patients are advised to await formal FDA guidance before adjusting treatment protocols.